COMMUNIQUÉS West-GlobeNewswire

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
02/03/2026
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE [...]
Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference
02/03/2026
New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system TUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard [...]
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
02/03/2026
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday [...]
Biomimetic Innovations Ltd Announces Upcoming Clinical Study of OsStic™ Injectable Synthetic Bone Void Filler in Tibial Plateau Fracture Fixation
02/03/2026
SHANNON, Ireland, March 02, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed, an Irish medical device company specialising in biomimetic materials, today announced approval by MHRA for a [...]
Humacyte To Participate in Upcoming Investor Conferences
02/03/2026
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
02/03/2026
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
02/03/2026
MISSISSAUGA, Ontario, March 02, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) is pleased to announce that it has successfully closed the previously-announced acquisition of Oral Science Inc [...]
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
02/03/2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Tectonic Therapeutic to Participate in March Investor Conferences
02/03/2026
WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Award-Winning Speaker Mike Veny Launches “Coffee with Mike” Mental Health Podcast for Workplace Leaders
02/03/2026
New podcast explores employee wellness, workplace mental health, and belonging strategies for leaders and organizations NEW YORK, New York, March 02, 2026 (GLOBE NEWSWIRE) -- Lovely Refinement CEO and mental health [...]
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 [...]
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
02/03/2026
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care [...]
Living with a Rare Disease: A Pastor’s Journey Finding the Right Care and Treatment for NF1-PN
02/03/2026
STAMFORD, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Did you know neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) is a rare genetic disorder that can cause tumors to grow along nerves, leading to pain, [...]
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
02/03/2026
-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera º for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American [...]
SAB BIO to Participate in Upcoming Investor Conferences
02/03/2026
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Replimune to Present at Two Upcoming Investor Conferences
02/03/2026
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members [...]
Trevi Therapeutics to Participate in Upcoming March Conferences
02/03/2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
02/03/2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
02/03/2026
- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip [...]

Pages